Member access

4-Traders Homepage  >  Shares  >  Mercato Continuo Espanol  >  Grifols SA    GRF   ES0171996012

GRIFOLS SA (GRF)

27
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Mercato Continuo Espanol
04/09/2014 04/10/2014 04/11/2014 04/14/2014 04/15/2014 Date
38.185(c) 37.555(c) 36.8(c) 36.3(c) 35.775(c) Last
1 367 948 1 153 121 1 319 164 1 258 078 1 253 001 Volume
-1.23% -1.65% -2.01% -1.36% -1.45% Change
More quotes
Company
Grifols specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (89.3%): products for... 
Surperformance© rating of Grifols SA
Trading Rating : Investor Rating :
More about the company
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | GRF | ES0171996012 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 3 523 M
EBIT 2014 1 017 M
Net income 2014 511 M
Debt 2014 3 175 M
Yield 2014 1,59%
Sales 2015 3 785 M
EBIT 2015 1 118 M
Net income 2015 601 M
Debt 2015 2 817 M
Yield 2015 1,91%
PER 2014 23,49
PER 2015 20,22
EV / Sales 2014 4,06x
EV / Sales 2015 3,68x
Capitalization 11 119 M
More Financials
Latest news on GRIFOLS SA
1d ago FLUOR NEW : -Designed and Built Plasma Fractionation Facility Awarded ISPE 2014 ..
7d agoDJNovartis Names New Alcon, Sandoz Division Heads -- Update
04/03 GRIFOLS : opens new plasma fractionation plant in Spain Download (28.8 Kb)
03/31 GRIFOLS : Japanese Red Cross selects Grifols as partner for nucleic acid screeni..
03/17 GRIFOLS : average cost of debt below 3.5% after a reduction of more than 2 point..
02/27 GRIFOLS SA : Grifols’ sales rose by 4.6% to Euros 2,742 million in 2013 Do..
02/13 GRIFOLS SA : Grifols Therapeutics Assigned Patent
01/08 GRIFOLS SA : Vall d'Hebron Research Institute (VHRI) collaborates with Grifols t..
2013 GRIFOLS SA : Vall d'Hebron Research Institute (VHRI) collaborates with Grifols t..
2013 GRIFOLS SA : Grifols Therapeutics Assigned Patent
2013 Novartis CEO says can spend $4-$6 billion a year on buys -paper
2013 Novartis sweetens investors with $5 billion share buyback
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
Grifols SA : Income Statement Evolution
More Financials
EPS Revisions
Grifols SA : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF